ArticleInternational journal of clinical and experimental pathology2015
Survivin contributes to the progression of diabetic retinopathy through HIF-1α pathway.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- NADPH Oxidase 3: Beyond the Inner Ear.Antioxidants (Basel, Switzerland) · 2024Review
- Comparison of HIF-1α and survivin levels in patients with diabetes and retinopathy of varying severity.Arquivos brasileiros de oftalmologia · 2024Article
- Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications.Frontiers in pharmacology · 2023Review
- The Role of Survivin and Transcription Factor FOXP1 in Scarring After Glaucoma Surgery.Translational vision science & technology · 2022Article
- Sanguinarine Reverses Pulmonary Vascular Remolding of Hypoxia-Induced PHFrontiers in pharmacology · 2021Article
- Uncovering the protective mechanism of Taohong Siwu decoction against diabetic retinopathy via HIF-1 signaling pathway based on network analysis and experimental validation.BMC complementary medicine and therapies · 2020Article
- The involvement of the mGluR5-mediated JNK signaling pathway in rats with diabetic retinopathy.International ophthalmology · 2019Article
- Molecular mechanism of the role of carbamyl erythropoietin in treating diabetic retinopathy rats.Experimental and therapeutic medicine · 2018Article
- GLP-1 Treatment Improves Diabetic Retinopathy by Alleviating Autophagy through GLP-1R-ERK1/2-HDAC6 Signaling Pathway.International journal of medical sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxia plays a critical role in the formation of diabetic retinopathy (DR). Hypoxia inducible factor-1α (HIF-1α) and survivin are upregulated following hypoxia, and contribute to the angiogenesis in cancer. The goal of our study was to investigate if the expression of HIF-1α and survivin is related to the retinal vascular change of rats with different stages of diabetes mellitus (DM). Wistar rats were randomly divided into DM for 1 month (DM1) group, DM3, DM6 group and normal control group. Streptozotocin (STZ) was used to induce diabetic rat models. Retinal vascular digest preparation was taken to observe the change of retinal microvessels. The expression of HIF-1α and survivin was determined by real-time PCR and Western blot. In DM3 group, capillaries became circuitous and irregular. Acellular capillary were detected in DM6 group. In the same time, the number of pericytes significantly decreased in DM3 and DM6 groups. The expressions of HIF-1α were more increased in the DM3 and DM6 groups. However, the expressions of survivin only were upregulated in DM6 group .These data suggest that HIF-1α induced the upregulation of survivin in the early stage of DR. Survivin contributed to the development and progression of DR through the HIF-1α pathway and become an important progression marker of DR.
Indexed as
Identifiers
26464661PMC4583893W2410834892What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.